Diabetes

Mechanistic insights into how Semaglutide functions as an anti-obesity/diabetic drug : Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: Semaglutide (trade name:Victoza, Saxenda), a glucagon-like peptide-1 agonist used in the treatment of diabetes, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 19/February/2021, 10.43 pm
Mechanistic insights into how Semaglutide functions as an anti-obesity/diabetic drug : Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: Semaglutide (trade name:Victoza, Saxenda), a glucagon-like peptide-1 agonist used in the treatment of diabetes, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 19/February/2021, 10.43 pm 960 720

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Curing, preventing and reversing diabetes with a commonly available antiasthmatic drug Montelukast: Montelukast-based therapy for TIIDM and obesity-associated metabolic deficits: Montelukast (trade name: Singulair and others), a vasodilator used in the treatment of asthma, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/March/2020, 11.08 pm
Curing, preventing and reversing diabetes with a commonly available antiasthmatic drug Montelukast: Montelukast-based therapy for TIIDM and obesity-associated metabolic deficits: Montelukast (trade name: Singulair and others), a vasodilator used in the treatment of asthma, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/March/2020, 11.08 pm 960 720

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: TICAM1/TRIF[Toll-like receptor adaptor molecule1/TIR-domain-containing adapter-inducing interferon-beta] decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/February/2020, 11.12 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: TICAM1/TRIF[Toll-like receptor adaptor molecule1/TIR-domain-containing adapter-inducing interferon-beta] decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/February/2020, 11.12 pm 960 720

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule…

read more

Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am
Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am 960 720

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

New Mechanistic and functional  insights into how Teneligliptin mitigates complications of diabetes and obesity:  Teneligliptin (brand names: Tenelin), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 4/September/2019, 9.30 am
New Mechanistic and functional  insights into how Teneligliptin mitigates complications of diabetes and obesity:  Teneligliptin (brand names: Tenelin), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 4/September/2019, 9.30 am 960 720

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

New Mechanistic and functional insights into how Vildagliptin mitigates complications of diabetes and obesity:  Vildagliptin/LAF237 (brand names: Galvus/Vildagluse/Gliptus), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 25/August/2019, 11.49 pm
New Mechanistic and functional insights into how Vildagliptin mitigates complications of diabetes and obesity:  Vildagliptin/LAF237 (brand names: Galvus/Vildagluse/Gliptus), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 25/August/2019, 11.49 pm 960 720

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more
Start Typing